Barclays PLC Sangamo Therapeutics, Inc Transaction History

Barclays PLC

$854 Billion
Q3 2025

A detailed history of Barclays PLC transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Barclays PLC holds 1 shares of SGMO stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 1 -0.0%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.66 - $1.37 $41,743 - $86,648	-63,247 Reduced 100.0%	1 $0
Q4 2024 Feb 13, 2025	BUY	$0.78 - $2.87 $49,332 - $181,518	63,247 Added 6324700.0%	63,248 $65,000
Q3 2024 Nov 15, 2024	SELL	$0.32 - $1.1 $17,443 - $59,962	-54,511 Reduced 100.0%	1 $0
Q2 2024 Aug 14, 2024	SELL	$0.36 - $0.65 $60,315 - $108,902	-167,543 Reduced 75.45%	54,512 $19,000
Q1 2024 May 15, 2024	SELL	$0.42 - $1.38 $42,979 - $141,218	-102,332 Reduced 31.55%	222,055 $149,000

Q4 2023 Feb 15, 2024	BUY	$0.3 - $0.63 $53,710 - $112,792	179,036 Added 123.17%	324,387 $176,000
Q3 2023 Nov 07, 2023	SELL	$0.58 - $1.47 $11,407 - $28,911	-19,668 Reduced 11.92%	145,351 $87,000
Q2 2023 Aug 03, 2023	SELL	$1.11 - $1.74 $237,536 - $372,354	-213,997 Reduced 56.46%	165,019 $214,000
Q1 2023 May 04, 2023	SELL	$1.66 - $3.67 $198,283 - $438,374	-119,448 Reduced 23.96%	379,016 $666,000
Q4 2022 Feb 13, 2023	BUY	$2.77 - $5.07 $368,199 - $673,924	132,924 Added 36.36%	498,464 $1.57 Million
Q3 2022 Nov 03, 2022	BUY	$4.27 - $6.39 $1.12 Million - $1.68 Million	262,234 Added 253.84%	365,540 $1.79 Million
Q2 2022 Aug 12, 2022	BUY	$3.28 - $6.21 $127,175 - $240,780	38,773 Added 60.08%	103,306 $428,000
Q1 2022 May 16, 2022	SELL	$5.23 - $7.82 $629,132 - $940,691	-120,293 Reduced 65.08%	64,533 $374,000
Q4 2021 Feb 14, 2022	BUY	$7.29 - $10.97 $523,414 - $787,635	71,799 Added 63.52%	184,826 $1.39 Million
Q3 2021 Nov 09, 2021	SELL	$9.01 - $12.01 $51,510 - $68,661	-5,717 Reduced 4.81%	113,027 $1.02 Million
Q2 2021 Aug 13, 2021	SELL	$10.17 - $12.64 $1.34 Million - $1.67 Million	-132,243 Reduced 52.69%	118,744 $1.42 Million
Q1 2021 May 13, 2021	SELL	$10.88 - $17.05 $948,420 - $1.49 Million	-87,171 Reduced 25.78%	250,987 $3.15 Million
Q4 2020 Feb 11, 2021	SELL	$9.23 - $18.18 $113,242 - $223,050	-12,269 Reduced 3.5%	338,158 $5.28 Million
Q3 2020 Nov 12, 2020	BUY	$9.38 - $12.48 $126,939 - $168,891	13,533 Added 4.02%	350,427 $3.31 Million
Q2 2020 Aug 12, 2020	BUY	$6.21 - $11.83 $443,897 - $845,620	71,481 Added 26.93%	336,894 $3.02 Million
Q1 2020 May 13, 2020	BUY	$5.05 - $8.85 $156,252 - $273,827	30,941 Added 13.2%	265,413 $1.69 Million
Q4 2019 Feb 10, 2020	BUY	$8.03 - $11.7 $156,906 - $228,618	19,540 Added 9.09%	234,472 $1.96 Million
Q3 2019 Nov 14, 2019	SELL	$9.05 - $12.22 $901,913 - $1.22 Million	-99,659 Reduced 31.68%	214,932 $1.94 Million
Q2 2019 Aug 14, 2019	BUY	$8.75 - $13.03 $1.36 Million - $2.02 Million	154,909 Added 97.01%	314,591 $3.39 Million
Q1 2019 May 15, 2019	BUY	$7.72 - $12.81 $756,899 - $1.26 Million	98,044 Added 159.06%	159,682 $1.52 Million
Q4 2018 Feb 14, 2019	SELL	$9.51 - $16.6 $155,355 - $271,177	-16,336 Reduced 20.95%	61,638 $708,000
Q3 2018 Nov 14, 2018	SELL	$13.05 - $19.05 $545,033 - $795,623	-41,765 Reduced 34.88%	77,974 $1.32 Million
Q2 2018 Aug 14, 2018	BUY	$13.9 - $19.8 $376,398 - $536,164	27,079 Added 29.22%	119,739 $1.7 Million
Q1 2018 May 15, 2018	BUY	$16.7 - $26.35 $196,642 - $310,271	11,775 Added 14.56%	92,660 $1.76 Million
Q4 2017 Feb 14, 2018	BUY	$11.6 - $17.35 $536,268 - $802,090	46,230 Added 133.4%	80,885 $1.33 Million
Q3 2017 Nov 14, 2017	BUY	$8.4 - $15.0 $291,102 - $519,825	34,655	34,655 $520,000

Others Institutions Holding SGMO

# of Institutions

124

Shares Held

62.5M

Call Options Held

953K

Put Options Held

1.11M

View Full List

About SANGAMO THERAPEUTICS, INC

Ticker SGMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 156,552,992
Market Cap $68.9M
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...

More about SGMO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account